Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317005
Recruitment Status : Completed
First Posted : April 21, 2006
Last Update Posted : July 26, 2018
Information provided by:
Universidade Estadual de Londrina

Brief Summary:
Homocysteine recently gained access to the category of risk factor for the development of atherosclerotic cardiovascular disease in the general population. Chronic renal failure patients, even before being introduced to dialysis therapy have almost universal elevation of serum homocysteine; when on dialysis their mortality is above 50% related to cardiovascular disease that we might now speculate, with a contribution of potentially toxic levels of the aminoacid homocysteine.

Condition or disease Intervention/treatment Phase
Uremia Chronic Renal Failure Hemodialysis Hyperhomocysteinemia Cardiovascular Disease Drug: folate treatment Phase 4

Detailed Description:

We conducted a double blind , randomized, placebo controlled trial, for two years, enroling, simultaneously, 186 end-stage kidney disease patients of any cause, older than 18 years of age, stable on hemodialysis, assigned to receive either oral folic acid 10 mg three times a week on post dialysis sessions, under nurse supervision or an identical appearing placebo for the entire lenght of the study, from april 2003 to march 2005.

The two groups had similar baseline clinical and laboratory characteristics. There was no loss of follow-up. At admission, homocysteine serum levels were above 13,9 umol/L in 96.7% (median 25.0, range 9.3-104.0)with only five cases in the normal levels; homocysteine remained elevated at 6, 12 and 24 months on those receiving placebo; folate treatment significantly decreased total homocysteine levels to a median value of 10.5 umol/L (2.8 - 20.3)which remained at this level for the entire study time (P<0.001); every one was alive and tested at six months, sixty eight were either transplanted(15)or died (53) from cardiovascular disease(seventeen in the folic acid group and twenty one in the placebo (P>0.05)or other causes(15), after being included in the study. Intima-media wall thickness blinded measured at the common carotid artery decreased from 1.94+-0,59 mm to 1.67+-0.38 (P<0.001) with folate therapy and became thicker, from 1.86+-0.41 to 2.11+-0.48 mm in the placebo group.

In conclusion, folate treatment for two years was not effective on modifying cardiovascular death and non fatal cardiovascular events of this sample population with chronic uremia; however, the ultrasonographic evaluation of the common carotid arteries intima-media wall thickness at entry and twenty four months later unequivocally showed a significant thickness decrease with supervised folate intake.

Earlier prescription of folic acid might benefit patients with chronic renal failure,preventing cardiovascular deterioration

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 186 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Randomized Clinical Trial of Folate Therapy/Placebo for Reduction of Homocysteine Serum Levels in Uremic Patients and Influence on Cardiovascular Mortality
Study Start Date : April 2003
Study Completion Date : March 2005

Primary Outcome Measures :
  1. Lowering of Homocysteine blood levels in uremia.
  2. Prevention of cardiovascular events

Secondary Outcome Measures :
  1. Reduction of carotid intima-media thickness

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients stable on hemodialysis for 4 months or more
  • Eighteen years of age or older

Exclusion Criteria:

  • Potential kidney transplant from a living donor in the near future
  • Severe cardiovascular disease
  • Cancer and active inflammation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00317005

Layout table for location information
Hospital Universitario regional do Note do Parana
Londrina, Parana, Brazil, 86020-320
University Hospital, State University of Londrina
Londrina, Parana, Brazil, 86020-320
Sponsors and Collaborators
Universidade Estadual de Londrina
Layout table for investigator information
Study Director: Altair J Mocelin, MD PHD Nephrology, University Hospital, State University of Londrina
Layout table for additonal information Identifier: NCT00317005    
Other Study ID Numbers: UEL/CPG/Nefro/Hcy
First Posted: April 21, 2006    Key Record Dates
Last Update Posted: July 26, 2018
Last Verified: May 2005
Keywords provided by Universidade Estadual de Londrina:
chronic uremia
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Cardiovascular Diseases
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Malabsorption Syndromes
Metabolic Diseases
Vitamin B Deficiency
Deficiency Diseases
Nutrition Disorders